Skip to main content

Table 2 Clinical characteristics of major depressive patients (n = 78) at baseline and healthy controls (n = 10)

From: Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Characteristics

Control

SSRIs

Mirtazapine

P

R

NR

R

NR

N

10

19

16

22

21

 

Age, mean ± SD, year

67.4 ± 6.7

65.9 ± 12.3

62.4 ± 10.2

66.4 ± 8.8

66.8 ± 9.4

0.884

Gender, M:F, n

3:7

6:13

4:12

6:16

6:15

0.996

HAM-D score, mean ± SD

 

19.0 ± 3.11

20.6 ± 2.76

18.2 ± 2.64

20.2 ± 3.79

0.320

Onset age, mean ± SD, year

 

56.4 ± 14.2

57.6 ± 9.66

56.5 ± 15.6

55.1 ± 14.5

0.573

No. of episode, mean ± SD

 

2.58 ± 1.92

1.75 ± 0.86

2.64 ± 2.06

3.33 ± 2.83

0.376

Duration of current episode, mean ± SD, m

 

4.21 ± 3.60

9.56 ± 7.89

3.86 ± 3.12

7.19 ± 6.59

0.105

Antidepressant used, n (%)

     

0.956

 Escitalopram

 

2 (10.5)

1 (6.3)

   

 Fluoxetine

 

8 (42.1)

9 (56.3)

   

 Paroxetine

 

5 (26.3)

3 (18.8)

   

 Sertraline

 

4 (21.1)

3 (18.8)

   

 Mirtazapine

   

22

21

 
  1. HAM-D Hamilton Depression Rating Scale, NR nonresponders; R responder; SD standard deviation, SSRIs selective serotonin reuptake inhibitors